Following is a schedule of Joint Sessions at the 2011 ASH Annual Meeting:
back to top
ASH/ASCO Joint Symposium
December 11, 2011 9:30 AM-11:00 AM
San Diego Marriott Marquis & Marina
(Marriott Hall)
The ASH/ASCO Joint Symposium will review some of the best science from the 2011 ASCO Annual Meeting, and the presentations will be delivered by the investigators who contributed to these clinical research successes. Attendees who want an overview of the latest clinical oncology research to complement the research presented at the ASH annual meeting will find this session of value.
J. Evan
Sadler, MD, PhD
Washington University Medical School
St. Louis,
MO,
USA
Michael
P.
Link, MD
Stanford University School of Medicine
Palo Alto,
CA,
USA
Speaker(s):
Paul
B.
Chapman, MD
Memorial Sloan-Kettering Cancer Center
New York,
NY,
USA
Phase III randomized, open-label, multicenter trial (BRIM3) comparing BRAF inhibitor vemurafenib with dacarbazine (DTIC) in patients with V600E BRAF-mutated melanoma
Jonathan
A.
Ledermann, MD
University College London Cancer Institute and UCL Hospitals
London,
United Kingdom
Phase II randomized placebo-controlled study of olaparib (AZD2281) in patients with platinum-sensitive relapsed serous ovarian cancer (PSR SOC)
Apostolia
Maria
Tsimberidou, MD, PhD
The University of Texas MD Anderson Cancer Center
Houston,
TX,
USA
Personalized medicine in a phase I clinical trials program: The M. D. Anderson Cancer Center initiative
Petri
Bono, MD, PhD
Helsinki University Central Hospital and University of Helsinki
Helsinki,
Finland
Twelve versus 36 months of adjuvant imatinib (IM) as treatment of operable GIST with a high risk of recurrence: Final results of a randomized trial (SSGXVIII/AIO)
back to top
ASH/EHA Joint Symposium
December 11, 2011 12:30 PM-1:30 PM
San Diego Convention Center
(Hall AB)
Vaccines are one of the great triumphs of medical science and public health. However, at least five million to 10 million deaths per year could be prevented if vaccines were available for infectious diseases such as HIV/AIDS, malaria, tuberculosis, and other neglected tropical diseases. The powerful new tools of post-genomic science, combined with new approaches to vaccine research and organizing science on a global scale, offer great promise for the future of both vaccine development and global health.
J. Evan
Sadler, MD, PhD
Washington University Medical School
St. Louis,
MO,
USA
Ulrich
Jäger,
Medical University of Vienna
Vienna,
Austria
Speaker(s):
Alan
Bernstein, OC, PhD
Li Ka Shing Knowledge Institute and University of Toronto
Toronto,
ON,
Canada
Vaccines for Global Health: The Challenges and Opportunities
back to top
